Overview

This trial is a phase I/II study, which is designed to evaluate the safety, tolerance, pharmacokinetic characteristics, receptor occupancy (RO), immunogenicity and effectiveness of LBL-019 monotherapy or combined with anti-PD-1 antibody in patients with advanced malignant tumors.

Eligibility

Inclusion Criteria:

        1.Agree to comply with the trial treatment plan and visit plan, voluntarily agree to sign
        the informed consent form;
        2.18-75 years old (including boundary value), no gender limit;
        3. previous standard treatment failed, no standard treatment or standard treatment is not
        applicable at this stage;
        4.The expected survival time is at least 12 weeks;
        Exclusion Criteria:
          1. Have received chemotherapy, radiotherapy, biological therapy, endocrine therapy,
             immunotherapy and other anti-tumor treatments within 4 weeks before using the study
             drug for the first time；
          2. Received any other investigational drug or treatment that is not on the market within
             4 weeks prior to the initial use of the investigational drug;
          3. Women who are pregnant or breastfeeding;
          4. The investigator believes that the subject has other conditions that may affect
             compliance or are not suitable for participating in the study